278 related articles for article (PubMed ID: 25504439)
1. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.
Vujic I; Sanlorenzo M; Posch C; Esteve-Puig R; Yen AJ; Kwong A; Tsumura A; Murphy R; Rappersberger K; Ortiz-Urda S
Oncotarget; 2015 Jan; 6(2):969-78. PubMed ID: 25504439
[TBL] [Abstract][Full Text] [Related]
2. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
Posch C; Moslehi H; Feeney L; Green GA; Ebaee A; Feichtenschlager V; Chong K; Peng L; Dimon MT; Phillips T; Daud AI; McCalmont TH; LeBoit PE; Ortiz-Urda S
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):4015-20. PubMed ID: 23431193
[TBL] [Abstract][Full Text] [Related]
3. Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma.
Wei BR; Michael HT; Halsey CH; Peer CJ; Adhikari A; Dwyer JE; Hoover SB; El Meskini R; Kozlov S; Weaver Ohler Z; Figg WD; Merlino G; Simpson RM
Pigment Cell Melanoma Res; 2016 Nov; 29(6):643-655. PubMed ID: 27463366
[TBL] [Abstract][Full Text] [Related]
4. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
[TBL] [Abstract][Full Text] [Related]
5. Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer lines.
Leung EY; Kim JE; Askarian-Amiri M; Rewcastle GW; Finlay GJ; Baguley BC
PLoS One; 2014; 9(8):e105792. PubMed ID: 25170609
[TBL] [Abstract][Full Text] [Related]
6. Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.
Vujic I; Posch C; Sanlorenzo M; Yen AJ; Tsumura A; Kwong A; Feichtenschlager V; Lai K; Arneson DV; Rappersberger K; Ortiz-Urda SM
Oncotarget; 2014 Sep; 5(17):7936-44. PubMed ID: 25277205
[TBL] [Abstract][Full Text] [Related]
7. Effects and Mechanisms of Metformin on the Proliferation of Esophageal Cancer Cells
Tang JC; An R; Jiang YQ; Yang J
Cancer Res Treat; 2017 Jul; 49(3):778-789. PubMed ID: 27857021
[TBL] [Abstract][Full Text] [Related]
8. Effect of Metformin in Combination With Trametinib and Paclitaxel on Cell Survival and Metastasis in Melanoma Cells.
Lee Y; Park D
Anticancer Res; 2021 Mar; 41(3):1387-1399. PubMed ID: 33788730
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
Anderson JL; Park A; Akiyama R; Tap WD; Denny CT; Federman N
PLoS One; 2015; 10(9):e0133610. PubMed ID: 26402468
[TBL] [Abstract][Full Text] [Related]
10. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
[TBL] [Abstract][Full Text] [Related]
11. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
12. Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.
Kiessling MK; Curioni-Fontecedro A; Samaras P; Lang S; Scharl M; Aguzzi A; Oldrige DA; Maris JM; Rogler G
PLoS One; 2016; 11(1):e0147682. PubMed ID: 26821351
[TBL] [Abstract][Full Text] [Related]
13. Effects of miR-145-5p through NRAS on the cell proliferation, apoptosis, migration, and invasion in melanoma by inhibiting MAPK and PI3K/AKT pathways.
Liu S; Gao G; Yan D; Chen X; Yao X; Guo S; Li G; Zhao Y
Cancer Med; 2017 Apr; 6(4):819-833. PubMed ID: 28332309
[TBL] [Abstract][Full Text] [Related]
14. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
Atefi M; Titz B; Avramis E; Ng C; Wong DJ; Lassen A; Cerniglia M; Escuin-Ordinas H; Foulad D; Comin-Anduix B; Graeber TG; Ribas A
Mol Cancer; 2015 Feb; 14(1):27. PubMed ID: 25645078
[TBL] [Abstract][Full Text] [Related]
15. A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.
Nagler A; Vredevoogd DW; Alon M; Cheng PF; Trabish S; Kalaora S; Arafeh R; Goldin V; Levesque MP; Peeper DS; Samuels Y
Pigment Cell Melanoma Res; 2020 Mar; 33(2):334-344. PubMed ID: 31549767
[TBL] [Abstract][Full Text] [Related]
16. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.
Algazi AP; Esteve-Puig R; Nosrati A; Hinds B; Hobbs-Muthukumar A; Nandoskar P; Ortiz-Urda S; Chapman PB; Daud A
Pigment Cell Melanoma Res; 2018 Jan; 31(1):110-114. PubMed ID: 28921907
[TBL] [Abstract][Full Text] [Related]
17. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
[TBL] [Abstract][Full Text] [Related]
18. Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy.
Zhang YX; van Oosterwijk JG; Sicinska E; Moss S; Remillard SP; van Wezel T; Bühnemann C; Hassan AB; Demetri GD; Bovée JV; Wagner AJ
Clin Cancer Res; 2013 Jul; 19(14):3796-807. PubMed ID: 23714727
[TBL] [Abstract][Full Text] [Related]
19. Epithelial to mesenchymal transition is associated with rapamycin resistance.
Holder AM; Akcakanat A; Adkins F; Evans K; Chen H; Wei C; Milton DR; Li Y; Do KA; Janku F; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(23):19500-13. PubMed ID: 25944619
[TBL] [Abstract][Full Text] [Related]
20. Combined mTOR/MEK inhibition prevents proliferation and induces apoptosis in NF2-mutant tumors.
Li N; Lu XY; Shi WY; Mao FJ; Yang XY; Luo YB; Li W
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5874-5883. PubMed ID: 31298338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]